12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Mirapexin pramipexole regulatory update

FDA issued a drug safety communication warning of a possible risk of heart failure in patients taking Boehringer's Mirapex pramipexole to treat Parkinson's disease and primary restless leg syndrome (RLS). FDA said...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >